A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard Therapy.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2014
At a glance
- Drugs Cediranib (Primary) ; Lomustine
- Indications Brain cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned end date changed from Dec 2008 to Mar 2009 as reported by ClinicalTrials.gov.